Penpulimab-kcqx – New orphan drug approval
April 24, 2025 - Akeso announced the FDA approval of penpulimab-kcqx in combination with either cisplatin or carboplatin and gemcitabine, for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) and as a single agent, for the treatment of adults with metastatic nonkeratinizing NPC and disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.
Top